SLAMF8 (SLAM Family Member 8)

Mechanistically, we demonstrated that SLAMF8 promotes the polarization of macrophages toward the M2 phenotype via the PI3K/AKT and JAK/STAT3 signaling pathways. In summary, this study confirmed that inhibiting SLAMF8 exerts an antitumor effect by reversing the immunosuppressive tumor microenvironment in CRC, providing new therapeutic targets and strategies for combined immunotherapy.

Elevated SLAMF8 expression in metastatic melanoma is associated with improved patient survival, suggesting its utility as a prognostic biomarker. Furthermore, its tumor-suppressive effects and immune-regulatory functions highlight SLAMF8 as a promising therapeutic target for melanoma treatment strategies.

This study demonstrates that SLAMF8 enhances PCa metastasis via the TLR4-NF-κB pathway. SLAMF8 is a potential predictor of distant metastasis and a promising target for PCa immunotherapy.

This review synthesizes current insights into SLAMF8's biological roles and clinical relevance, positioning it as a compelling interface between immune homeostasis and disease. As research deepens, SLAMF8 may redefine therapeutic approaches across oncology, immunology, and regenerative medicine.

This study confirmed that DNA methylation markers can effectively predict the progression and prognosis of clear cell renal cell carcinoma (ccRCC), providing a highly efficient and minimally invasive assessment tool for clinical practice.

P=N/A, N=2000, Recruiting, University of Sheffield | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jan 2024 --> Jun 2025

When PI3K inhibitors and Fc blockers were added after SLAMF8 knockdown, mouse macrophage phagocytosis, and FcR expression decreased. Our results suggest that SLAMF8 may impair FcR-mediated phagocytosis through the PI3K-Akt signaling pathway and negatively regulate the antitumor immune response.

Our work demonstrated that SLAMF8 promoted AS in patients with RA by inducing inflammation and apoptosis of foam cells via TLR4 signaling. Therefore, SLAMF8 could be a possible therapeutic spot for AS in RA patients.

Furthermore, the relationship between SLAMF8 expression and the therapeutic efficacy of the PD1 blockade agent, Sintilimab, treatment in gastric cancer was validated...Significant correlations were observed between SLAMF8 levels and pan-cancer tumorigenesis, tumor metabolism, and immunity. As a result, SLAMF8 may become an important prognostic biomarker in the majority of tumors and a hopeful gene target for immunotherapy against gastric cancer.

Dynamic changes in the immune microenvironment associated with tumor purity could correlate with a poor DMFS of low-purity PCa. The TPS can predict the DMFS of PCa. In addition, prostate cancer metastases may be related to immunosuppression caused by a disorder of the immune microenvironment.

Our study suggests that at day 5 post bronchoscopic thermal injury of NSCLC there appears to be activation of a T cell-mediated immune response which is driven by immune memory reactivation. This process is characterised by an increase in antigen presentation, T cell trafficking and T cell activation in the TME. The proliferation of CD4+ Tcm and CD8+ Tcm in blood would imply immune memory reactivation.

The mRNA expression level of SLAMF8 was positively correlated with the expression levels of multiple classic immune checkpoints and other SLAM family members. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis suggested that the pathways enriched in CRC tissues with high SLAMF8 expression were associated with the regulation of the tumor immune microenvironment.